细胞因子释放综合征的管理：新兴抗原特异性T细胞衔接免疫疗法的最新进展 - Suppr | 超能文献

相似文献

1

Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies.细胞因子释放综合征的管理：新兴抗原特异性T细胞衔接免疫疗法的最新进展

Immunotherapy. 2019 Jul;11(10):851-857. doi: 10.2217/imt-2019-0074. Epub 2019 Jun 4.

2

Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.嵌合抗原受体（CAR）T 细胞治疗中的细胞因子释放综合征和神经毒性的管理。

Expert Rev Hematol. 2019 Mar;12(3):195-205. doi: 10.1080/17474086.2019.1585238. Epub 2019 Mar 18.

3

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.ASTCT 细胞因子释放综合征和免疫效应细胞相关神经系统毒性的共识分级标准。

Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638. doi: 10.1016/j.bbmt.2018.12.758. Epub 2018 Dec 25.

4

Cytokine Release Syndrome Associated with T-Cell-Based Therapies for Hematological Malignancies: Pathophysiology, Clinical Presentation, and Treatment.与血液系统恶性肿瘤的 T 细胞疗法相关的细胞因子释放综合征：发病机制、临床表现和治疗。

Int J Mol Sci. 2021 Jul 17;22(14):7652. doi: 10.3390/ijms22147652.

5

Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy.嵌合抗原受体 T 细胞治疗相关细胞因子释放综合征。

Biol Blood Marrow Transplant. 2019 Apr;25(4):e123-e127. doi: 10.1016/j.bbmt.2018.12.756. Epub 2018 Dec 23.

6

Management Principles Associated With Cytokine Release Syndrome.与细胞因子释放综合征相关的管理原则。

Semin Oncol Nurs. 2019 Oct;35(5):150931. doi: 10.1016/j.soncn.2019.08.010. Epub 2019 Aug 31.

7

Plasma Exchange Can Be an Alternative Therapeutic Modality for Severe Cytokine Release Syndrome after Chimeric Antigen Receptor-T Cell Infusion: A Case Report.血浆置换可作为嵌合抗原受体 T 细胞输注后严重细胞因子释放综合征的一种替代治疗方法：病例报告。

Clin Cancer Res. 2019 Jan 1;25(1):29-34. doi: 10.1158/1078-0432.CCR-18-1379. Epub 2018 Oct 15.

8

T-cell Immunotherapy and Cardiovascular Disease: Chimeric Antigen Receptor T-cell and Bispecific T-cell Engager Therapies.T 细胞免疫疗法与心血管疾病：嵌合抗原受体 T 细胞和双特异性 T 细胞衔接器疗法。

Heart Fail Clin. 2022 Jul;18(3):443-454. doi: 10.1016/j.hfc.2022.02.008.

9

Cytokine release syndrome and cancer immunotherapies - historical challenges and promising futures.细胞因子释放综合征与癌症免疫疗法——历史挑战与光明前景。

Front Immunol. 2023 May 25;14:1190379. doi: 10.3389/fimmu.2023.1190379. eCollection 2023.

10

Continuous renal replacement therapy in cytokine release syndrome following immunotherapy or cellular therapies?免疫治疗或细胞治疗后细胞因子释放综合征中的持续肾脏替代治疗？

J Immunother Cancer. 2020 May;8(1). doi: 10.1136/jitc-2020-000742.

引用本文的文献

1

Discordant CAR-T cell signaling: implications of divergence from physiological T cell activation.不一致的嵌合抗原受体T细胞信号传导：偏离生理性T细胞活化的影响

J Transl Med. 2025 Jul 25;23(1):834. doi: 10.1186/s12967-025-06857-w.

2

Combined IVIG and High-Dose Systemic Corticosteroids for the Management of Pembrolizumab-Induced Cytokine Release Syndrome in Lung Adenocarcinoma.静脉注射免疫球蛋白联合大剂量全身皮质类固醇治疗肺腺癌中帕博利珠单抗诱导的细胞因子释放综合征

Respirol Case Rep. 2025 May 19;13(5):e70215. doi: 10.1002/rcr2.70215. eCollection 2025 May.

3

CAR-T therapy dilemma and innovative design strategies for next generation.